NCT02915783View on ClinicalTrials.gov

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 20, 2017

Primary Completion Date

November 2, 2021

Study Completion Date

November 2, 2021

Conditions

Non Clear Cell Renal Cell Carcinoma (nccRCC)

Interventions

DRUG

lenvatinib

4 mg and 10 mg capsules

DRUG

everolimus

5 mg tablets

Trial Locations (8)

10065

Weill Cornell Medical College, New York

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

48201

Barbara Ann Karmanos Cancer Institute, Detroit

60612

Rush University Medical Center, Chicago

63110

Washington University, St Louis

75254

Texas Oncology, Dallas

84112

Huntsman Cancer Institute, Salt Lake City

02214

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT02915783 - A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease | Biotech Hunter | Biotech Hunter